Cutting-edge approaches to combat tumor development involve transplantation of anti-tumor T cells and natural killer cells. Natural killer (NK) cells belong to a greater family of innate lymphoid cells which includes the more recently described group 1, 2, and 3 innate lymphoid cells (ILCs). Unlike NK and T cells, the role of non-NK ILCs in tumor immunity remains unclear. In this episode, Kellen highlights a 2020 report in Nature describing the role of ILC2s in pancreatic cancer. The article was written by John Alec Moral and colleagues and is titled “ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity”.Paper: https://www.nature.com/articles/s41586-020-2015-4Review: https://pubmed.ncbi.nlm.nih.gov/30209347/Please take a few minutes to write us a review wherever you listen to podcasts -- it will help us better spread science!Want to learn more? Check out the Inflammatory Content website www.inflammatorycontent.comFinally, please send any questions or comments to Kellen on Twitter @KellenCavagnero or email [email protected].